Australia's Radiopharm Theranostics rises after first patient dosed in lung cancer trial
10/07/2024 03:10
** Shares of Radiopharm Theranostics RAD.AX rise as much
as 5.7% to A$0.037
** Stock set for best day since June 26
** Pharmaceutical co doses first patient in Phase-1 clinical
trial of RAD 204, which is being developed to cure non-small
cell lung cancer
** Stock has fallen 52.7% this year, as of last close
(Reporting by Shivangi Lahiri in Bengaluru)
((shivangi.lahiri@thomsonreuters.com))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%